Breast Cancer Susceptibility Genetic Testing; Where Should Medical Professionals Stand Between Providers and Customers?

Cancer had become the second leading cause of death in the United States in 1970 when National Cancer Act of 1971 was signed by President Nixon. Over the past few decades “War on Cancer” has urged the medical fraternity to try to decode this entity and strike the molecularly defined targets that are presumed to drive the cancer. Identification of breast cancer susceptibility genes BRCA1/2 therefore has been overwhelmingly hypothesized to be a keystone in this regard.1 It is worth reminding that together, BRCA1 /BRCA2 mutations account for about 20 to 25 percent of hereditary breast cancers2 and only about 5 to 10 percent of all breast cancers